Curevac sues BioNTech over COVID-19 vaccine's mRNA technology [FOX Business Network]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: FOX Business Network
German biopharmaceutical company CureVac sued BioNTech on Tuesday, seeking "fair compensation" for alleged infringement of intellectual property rights related to the mRNA technology that was used to develop Pfizer and BioNTech's COVID-19 vaccine "The CureVac intellectual property portfolio protects multiple inventions that are considered essential to the design and development of BioNTech's SARS CoV-2 mRNA vaccine, among others," CureVac said in a statement on Tuesday. BioNTech said that the company will "vigorously defend" its work "against all allegations of patent infringement." A medical worker fills a syringe with a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine. (Behrouz Mehri/Pool via REUTERS/File Photo / Reuters) "We are aware that it is not unusual that other companies in the pharmaceutical industry , having witnessed the success of COMIRNATY®, are now suggesting that the vaccine potentially infringes their intellectual property rights," the Germ
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Scholz promises support for pharma sector in Germany as Merck invests [Reuters]Reuters
- Scholz promises support for pharma sector in Germany as Merck invests [Yahoo! Finance]Yahoo! Finance
- BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024GlobeNewswire
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $107.00 price target on the stock.MarketBeat
BNTX
Earnings
- 3/20/24 - Miss
BNTX
Sec Filings
- 4/8/24 - Form 6-K
- 4/8/24 - Form 6-K
- 3/25/24 - Form 6-K
- BNTX's page on the SEC website